Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Therapeutic Efficacy of Adipose-Derived Stem Cells for Bleomycin-Induced Idiopathic Pulmonary Fibrosis: A Comparative Study of Intravenous versus Intratracheal Administration.

Ng YY., Chiang CY., Ni YL., Shen HT., Lee CY., Lee TP.

Animal Study on Systemic / IV, published in Cell J (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Cell J (2026)
Country
Iran
Reported sample size
—
Source database
PubMed
PMID
42001275
DOI
10.22074/cellj.2026.2066514.1886

Abstract (original English)

Objective To compare the therapeutic effects of intravenous (IV) and intratracheal (IT) delivery of adipose-derived stem cells (ADSCs) in a mouse model of bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF). Materials and methods In this experimental study, BALB/c mice were divided into 4 groups: control, BLM only, BLM+ADSC(IV), BLM+ADSC(IT). ADSCs were administered on day 14 after BLM induction. Outcomes measured on day 42 included mortality, body weight, lung edema, collagen deposition, fibrosis scoring, cytokine levels (TGF-β, SDF-1, IL-6, IL-1β, TNF-α), hydroxyproline, and leukocyte infiltration. Results ADSC(IT) reduced mortality more effectively than ADSC(IV). Both IV and IT mitigated weight loss and lung edema with no significant difference. Both routes significantly decreased collagen synthesis, collagen fiber accumulation, Ashcroft scores, and hydroxyproline levels. Both routes lowered TGF-β, α-SMA, TNF-α, IL-6, IL-1β, and SDF-1 levels, and reduced leukocyte infiltration and alveolar barrier dysfunction, with no significant difference between routes. Conclusion This design enables discrimination between route-dependent and route-independent therapeutic ef fects of ADSCs, thereby providing new insight into the optimization of stem cell delivery strategies for pulmo nary fibrosis. Importantly, whether the choice of deliv ery route differentially affects survival

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research